RESOURCES TO OPTIMIZE PRICING AND REIMBURSEMENT:

WHITE PAPERS

 

Medicare Part D: Closing The Coverage Gap

  

DOWNLOAD


Membership Management: Challenges and Best Practices

  

DOWNLOAD



Medicaid Drug Classification: Civil Monetary Penalties
 

DOWNLOAD



WEBINARS
  • Keeping up with the Reference Pricing Landscape & Trends and the Effects of the US's IPI (June 12, 2019) [Access Webinar]


  • Challenging Dynamics in Immuno-oncology: Access, Reimbursement, and Provider Perspectives (April) [Access Webinar]





IN THE MEDIA
  • Journal of Clinical Pathways May 2019 "CMS Policies Concerning CAR-T Therapies" [VISIT]

  • MedAd News
    • June 2019 "Market Access for Rare Disease Products" [VISIT]
    • February 2019 "Will the US Adopt Global Reference Pricing?" [VISIT]
Paper.png

  Keeping up with the Reference Pricing Landscape &
Trends and the Effects of the US's IPI

RESOURCES:

WHITE PAPERS

Medicare Part D: Closing The Coverage Gap [Download]
Membership Management: Challenges and Best Practices [Download] 
Medicaid Drug Classification: Civil Monetary Penalties [Download]

IN THE MEDIA

Journal of Clinical Pathways
  • "CMS Policies Concerning CAR-T Therapies" [VISIT]
MedAd News 
  • "Market Access for Rare Disease Products" [VISIT]
  • MedAd News "Will the US Adopt Global Reference Pricing?" [VISIT]

 

 


WEBINARS

Keeping up with the Reference Pricing Landscape & Trends and the Effects of the US's IPI (June 12, 2019)
[Access Webinar]



LEARN MORE 
  • EVERSANA rare patient adherence Avg.
    *industry average is 58-62%,
    **Case Study results vary

  • Covered lives access within four months of launch

  • One million square feet.
    99.98% unit level accuracy

Eversana_Logo_H_RGB.PNG

Keeping up with the Reference Pricing Landscape &
Trends and the Effects of the US's IPI

Ready to Optimize Pricing and Reimbursement?

Connect with an Expert